451 related articles for article (PubMed ID: 23755755)
1. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
2. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
3. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
5. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
[TBL] [Abstract][Full Text] [Related]
6. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial.
Bonten TN; Saris A; van Oostrom MJ; Snoep JD; Rosendaal FR; Zwaginga J; Eikenboom J; van der Meer PF; van der Bom JG
Thromb Haemost; 2014 Dec; 112(6):1209-18. PubMed ID: 25208590
[TBL] [Abstract][Full Text] [Related]
7. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
8. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
Van Ryn J; Kink-Eiband M; Kuritsch I; Feifel U; Hanft G; Wallenstein G; Trummlitz G; Pairet M
J Clin Pharmacol; 2004 Jul; 44(7):777-84. PubMed ID: 15199082
[TBL] [Abstract][Full Text] [Related]
9. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
11. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
12. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
[TBL] [Abstract][Full Text] [Related]
13. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
14. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.
Capone ML; Sciulli MG; Tacconelli S; Grana M; Ricciotti E; Renda G; Di Gregorio P; Merciaro G; Patrignani P
J Am Coll Cardiol; 2005 Apr; 45(8):1295-301. PubMed ID: 15837265
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
Catella-Lawson F; Reilly MP; Kapoor SC; Cucchiara AJ; DeMarco S; Tournier B; Vyas SN; FitzGerald GA
N Engl J Med; 2001 Dec; 345(25):1809-17. PubMed ID: 11752357
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
Hong Y; Gengo FM; Rainka MM; Bates VE; Mager DE
Clin Pharmacokinet; 2008; 47(2):129-37. PubMed ID: 18193919
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]